Frank Boess

4.9k citations

45 papers · 3.2k · 1 hit paper · h-index 24

Impact in

Cellular and Molecular Neuroscience top 1%
- Neurotransmitter Receptor Influence on Behavior
- Neuroscience and Neuropharmacology Research
Pharmacology top 1%
- Cholinesterase and Neurodegenerative Diseases

Papers in

Cellular and Molecular Neuroscience 15
- Neurotransmitter Receptor Influence on Behavior 11
- Neuroscience and Neuropharmacology Research 5
Molecular Biology 20
- Receptor Mechanisms and Signaling 12
- Nicotinic Acetylcholine Receptors Study 11
- Ion channel regulation and function 4

Co-authors: Ian L. Martin (7 shared papers)Eric H. Karran (1 shared paper)Viktor Lakics (1 shared paper)Andrew J. Sleight (13 shared papers)Anne Bourson (10 shared papers)Michael Bös (5 shared papers)Rudy Schreiber (2 shared papers)Jos Prickaerts (2 shared papers)
Journals: Neuropharmacology (6 papers)Journal of Neurochemistry (4 papers)Annals of the New York Academy of Sciences (3 papers)Molecular Pharmacology (3 papers)Alzheimer s & Dementia (3 papers)
Partner nations: Switzerland Germany United Kingdom

In The Last Decade

Frank Boess

45 papers receiving 3.0k citations

Frank Boess's Hit Papers

align trajectories log scale

Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease 2018 · 245 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2018 JAMA Neurology

Peers

Countries citing papers authored by Frank Boess

Since Specialization

Citations

This map shows the geographic impact of Frank Boess's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank Boess with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank Boess more than expected).

Fields of papers citing papers by Frank Boess

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank Boess. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank Boess. The network helps show where Frank Boess may publish in the future.

Co-authors

The 25 scholars most cited alongside Frank Boess, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Frank Boess Line = papers co-authored together Frank Boess links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 45 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Molecular biology of 5-HT receptors Neuropharmacology ·Frank Boess, Ian L. Martin	1994	598
2	Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues Neuropharmacology ·Viktor Lakics, Eric H. Karran, Frank Boess	2010	384
3	Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance Neuropharmacology ·Frank Boess, Martin Hendrix, Franz Josef van der Staay, Christina Erb, Rudy Schreiber, Wilma van Staveren, Jan de Vente, Jos Prickaerts, Arjan Blokland, Gerhard Koenig	2004	262
4	Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease JAMA Neurology ·Joseph J. Jankovic, Ira J. Goodman, Beth Safirstein, Tonya Marmon, Dale B. Schenk, Martin Koller, Wagner M. Zago, DANIEL K. NESS, Sue G. Griffith, Michael J Grundman, Jay Soto, Susanne Ostrowitzki, Frank Boess, Meret Martin‐Facklam, Joseph F. Quinn, Stuart Isaacson, Omid Omidvar, Aaron L. Ellenbogen, Gene G. Kinney Hit paper breakdown →	2018	245
5	EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors Neuropharmacology ·Jos Prickaerts, Nick P. van Goethem, Richard Chesworth, Gideon Shapiro, Frank Boess, Christoph Methfessel, Olga A.H. Reneerkens, Dorothy G. Flood, Dana C. Hilt, Maria S. Gawryl, Sonia Bertrand, Daniel Bertrand, Gerhard König	2011	183
6	Characterization of Ro 04‐6790 and Ro 63‐0563: potent and selective antagonists at human and rat 5‐HT6 receptors British Journal of Pharmacology ·Andrew J. Sleight, Frank Boess, Michael Bös, Bernard Levet‐Trafit, Claus Riemer, Anne Bourson	1998	159
7	AR-R 17779 improves social recognition in rats by activation of nicotinic α7 receptors Psychopharmacology ·Marja van Kampen, Karin Selbach, Renate Schneider, Elleonore Schiegel, Frank Boess, Rudy Schreiber	2004	143
8	The Novel α7 Nicotinic Acetylcholine Receptor Agonist N-[(3 R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide Improves Working and Recognition Memory in Rodents Journal of Pharmacology and Experimental Therapeutics ·Frank Boess, Jean De Vry, Christina Erb, Timo Fleßner, Martin Hendrix, Joachim E. A. Luithle, Christoph Methfessel, Bernd Riedl, Katrin Schnizler, Franz Josef van der Staay, Marja van Kampen, Welf Burkhard Wiese, Gerhard Koenig	2007	128
9	Ultrastructure of the 5‐Hydroxytryptamine3 Receptor Journal of Neurochemistry ·Frank Boess, Rameen Beroukhim, Ian L. Martin	1995	120
10	Investigation of stretching behaviour induced by the selective 5‐HT6 receptor antagonist, Ro 04–6790, in rats British Journal of Pharmacology ·J. Bentley, Anne Bourson, Frank Boess, Kevin C.F. Fone, Charles Alexander Marsden, Nadine Petit, Andrew J. Sleight	1999	95
11	Functional and Radioligand Binding Characterization of Rat 5-HT 6 Receptors Stably Expressed in HEK293 Cells Neuropharmacology ·Frank Boess, Frederick J. Monsma, C. CAROLO, Valerie Meyer, Alain Rudler, Catherine Zwingelstein, Andrew J. Sleight	1997	77
12	Involvement of 5‐HT6 receptors in nigro‐striatal function in rodents British Journal of Pharmacology ·Anne Bourson, Frank Boess, Michael Bös, Andrew J. Sleight	1998	75
13	The 5-Hydroxytryptamine6 Receptor-Selective radioligand [3H]Ro 63–0563 Labels 5-Hydroxytryptamine Receptor Binding Sites in Rat and Porcine Striatum Molecular Pharmacology ·Frank Boess, Claus Riemer, Michael Bös, Jane Bentley, Anne Bourson, Andrew J. Sleight	1998	69
14	Analysis of the Ligand Binding Site of the 5-HT 3 Receptor Using Site Directed Mutagenesis: Importance of Glutamate 106 Neuropharmacology ·Frank Boess, Lucinda J. Steward, Joy A. Steele, D. Liu, Joanne Reid, Thora A. Glencorse, Ian L. Martin	1997	68
15	Progressive Decline in Gray and White Matter Integrity in de novo Parkinson’s Disease: An Analysis of Longitudinal Parkinson Progression Markers Initiative Diffusion Tensor Imaging Data Frontiers in Aging Neuroscience ·Kirsten I. Taylor, Fabio Sambataro, Frank Boess, Alessandro Bertolino, Juergen Dukart	2018	62
16	Correlation between 5-HT7 receptor affinity and protection against sound-induced seizures in DBA/2J mice Naunyn-Schmiedeberg s Archives of Pharmacology ·Anne Bourson, Véronique Kapps, Catherine Zwingelstein, Alain Rudler, Frank Boess, Andrew J. Sleight	1997	51
17	Importance of Phenylalanine 107 in Agonist Recognition by the 5-Hydroxytryptamine3A Receptor Molecular Pharmacology ·Lucinda J. Steward, Frank Boess, Joy A. Steele, D. Liu, NS Wong, Ian L. Martin	2000	41
18	Tadalafil Once Daily in Men with Erectile Dysfunction: An Integrated Analysis of Data Obtained from 1913 Patients from Six Randomized, Double-blind, Placebo-controlled, Clinical Studies European Urology ·Hartmut Porst, Mauro Gacci, Hartwig Büttner, Carsten Henneges, Frank Boess	2013	40
19	Identification of Residues in Transmembrane Regions III and VI that Contribute to the Ligand Binding Site of the Serotonin 5‐HT6 Receptor Journal of Neurochemistry ·Frank Boess, Frederick J. Monsma, Andrew J. Sleight	1998	39
20	The Putative 5‐ht6 Receptor: Localization and Function Annals of the New York Academy of Sciences ·Andrew J. Sleight, Frank Boess, Michael Bös, Anne Bourson	1998	38

About Frank Boess

Frank Boess is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology, Neurology, Organic Chemistry and Physiology, having authored 45 papers that have together received 3.2k indexed citations. Recurring topics across this work include Receptor Mechanisms and Signaling (12 papers), Nicotinic Acetylcholine Receptors Study (11 papers), Neurotransmitter Receptor Influence on Behavior (11 papers), Chemical synthesis and alkaloids (6 papers), Parkinson's Disease Mechanisms and Treatments (5 papers), Neuroscience and Neuropharmacology Research (5 papers), Ion channel regulation and function (4 papers) and Sexual function and dysfunction studies (4 papers). The work is most often cited by research in Cellular and Molecular Neuroscience (1.4k citations), Pharmacology (602 citations), Molecular Biology (1.9k citations), Biological Psychiatry (56 citations) and Neurology (303 citations). Frank Boess has collaborated with scholars based in Switzerland, Germany and United Kingdom. Frequent co-authors include Ian L. Martin, Eric H. Karran, Viktor Lakics, Andrew J. Sleight, Anne Bourson, Michael Bös, Rudy Schreiber, Jos Prickaerts, Rameen Beroukhim and Claus Riemer. Their work appears in journals such as Neuropharmacology, Journal of Neurochemistry, Annals of the New York Academy of Sciences, Molecular Pharmacology and Alzheimer s & Dementia.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Frank Boess

Impact in

Papers in i

In The Last Decade

Frank Boess

Frank Boess's Hit Papers

Peers

Countries citing papers authored by Frank Boess

Fields of papers citing papers by Frank Boess

All Works

About Frank Boess

Explore authors with similar magnitude of impact

Papers in